Supplementary Materials:

Synthesis, docking and in vitro anticoagulant activity assay of

hybrid derivatives of pyrrolo[3,2,1-*ij*]quinolin-2(1*H*)-one as new

inhibitors of factor Xa and factor Xia

Article

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1*ij*]Quinolin-2(1*H*)-one as New Inhibitors of Factor Xa and Factor XIa

Nadezhda Novichikhina ¹, Ivan Ilin ^{2,3}, Anna Tashchilova ^{2,3}, Alexey Sulimov ^{2,3}, Danil Kutov ^{2,3}, Irina Ledenyova ¹, Mikhail Krysin ^{1,*}, Khidmet Shikhaliev ¹, Anna Gantseva ⁴, Ekaterina Gantseva ⁴, Nadezhda Podoplelova ^{5,6} and Vladimir Sulimov ^{2,3}

- ¹ Department of Organic Chemistry, Faculty of Chemistry, Voronezh State University, 1 Universitetskaya sq., Voronezh 394018, Russia; <u>podaneva_nadya@mail.ru</u> (N.N.); irairachem@yandex.ru (I.L.); <u>chocd261@chem.vsu.ru</u> (K.S.)
- ² Research Computing Center, Lomonosov Moscow State University, Moscow 119992, Russia; ivan.ilyin@srcc.msu.ru (I.I.); <u>at@dimonta.com</u> (A.T.); <u>as@dimonta.com</u> (A.S.); <u>dk@dimonta.com</u> (D.K.); <u>vs@dimonta.com</u> (V.S.)
- ³ Dimonta, Ltd., Moscow 117186, Russia
- ⁴ Faculty of Physics, Lomonosov Moscow State University, Moscow 119992, Russia; <u>gantceva.ar16@physics.msu.ru</u> (A.G.); <u>katia_gantseva@mail.ru</u> (E.G.)
- ⁵ Russian Children's Clinical Hospital of the Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation, Moscow 119571, Russia; podoplelovan@yandex.ru
- ⁶ Center for Theoretical Problems of Physicochemical Pharmakology, Moscow 119991, Russia
- * Correspondence: kaf261@rambler.ru; Tel.: +7–903–651–7482

Academic Editor: Athina Geronikaki Received: 29 March 2020; Accepted: 17 April 2020; Published: date



Figure S1. The docking pose of **7a** and **7b** in an active site of FXa. A methyl group in PQD of **7b** (purple carbon atoms) distorts the plane formed by thioxothiazolidineone and the scaffold which is observed for **7a** (blue carbon atoms). The distorted position of thioxothiazolidineone hinders favorable pi-pi interactions with Tyt99/Phe174.



Figure S2. The docking pose of **9a** (yellow carbon atoms) and **9c** (blue carbon atoms) in an active site of FXIa. The small distance between the scaffold of presented ligands near C⁹ position and Lys192 does not allow introducing bulky substituents at C⁹. Spheres based on van der Waals radii show this small distance between a fluorine atom of (a blue sphere) **9c** and a hydrogen atom of Lys192 (a gray sphere). Because of steric hindrance, **9a** cannot reproduce the binding mode of **9c**.

¹H, ¹³C NMR spectra and data of HPLC-MS-ESI analysis of PQ 7

(Z)-2-thioxo-5-(4,4,6-trimethyl-2-oxo-6-phenyl-2,4,5,6-tetrahydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-1-ylidene)thiazolidin-4-one 7a











(Z)-5-(4,4,6,9-tetramethyl-2-oxo-6-phenyl-2,4,5,6-tetrahydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-1-ylidene)-2-thioxothiazolidin-4-one 7b







(Z) - 5 - (6 - (4 - chlorophenyl) - 4, 4, 6, 8 - tetramethyl - 2 - oxo - 2, 4, 5, 6 - tetrahydro - 1 H - pyrrolo [3, 2, 1 - ij] quinolin - 1 - ylidene) - 2 - thioxothiazolidin - 1 - ylidene) - 2 - thioxothiazoli



4-one 7c







¹H, ¹³C NMR spectra and data of HPLC-MS-ESI analysis of PQD 14

Ethyl 4-((8-methoxy-4,4-dimethyl-1,2-dioxo--2,4-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)methyl)piperazine-1-carboxylate 14a











8-Methoxy-4,4-dimethyl-6-((4-phenylpiperazine-1-yl)methyl)-1H-pyrrolo[3,2,1-ij]quinolin-1,2(4H)-dione 14b



Ethyl 4-((8-fluoro-4,4-dimethyl-1,2-dioxo-2,4-dihydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-6-yl)methyl)piperazine-1-carboxylate 14c







6-((4-benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)methyl)-8-methoxy-4,4-dimethyl-1H-pyrrolo[3,2,1-ij]quinolin-1,2(4H)-dione



14d









6-((4-(4-fluorophenyl)piperazine-1-yl)methyl)-8-methoxy-4,4-dimethyl-1*H*-pyrrolo[3,2,1-*ij*]quinolin-1,2(4*H*)-dione 14e







6-((4-benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)methyl)-8-fluoro-4,4-dimethyl-1H-pyrrolo[3,2,1-ij]quinolin-1,2(4H)-dione



14f







¹H, ¹³C NMR spectra and data of HPLC-MS-ESI analysis of PQ 9

(Z)-Ethyl 4-((8-methoxy-4,4-dimethyl-2-oxo-1-(4-oxo-2-thioxothiazolidin-5-ylidene)-2,4-dihydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-6-

yl)methyl)piperazine-1-carboxylate 9a









(Z)-5-(8-methoxy-4,4-dimethyl-2-oxo-6-((4-phenylpiperazin-1-yl)methyl)-2,4-dihydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-1-ylidene)-2-

thioxothiazolidin-4-one 9b







(Z)-Ethyl 4-((8-fluoro-4,4-dimethyl-2-oxo-1-(4-oxo-2-thioxothiazolidin-5-ylidene)-2,4-dihydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-6-

C Zelinsky Institute of Organic Chemistry, Moscow; Bruker DRX500 SF=500.13 MHz {1H} SI=16K SW=10000 O1=4006 PW=12.0 AQ=1.638 RD=0.00 NS=1 SR=8.48 TE=299K 2 November 2017 Opr: Strelenko Yu.A.; Prep: L=9091; Solv: DMSO=d6; Found protons = 24 impurity* = 1.8 % CH, CH, 0 HN 9c 68 19 8.6 8.5 Willing Attal galing * ~ TMS Water DMSO-d5 0.16 30.14 30.14 13 12 11 10 9 14 8 5 3 7 6 4 2 53.16 8.65 8.78

yl)methyl)piperazine-1-carboxylate 9c







(Z)-5-(6-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-8-methoxy-4,4-dimethyl-2-oxo-2,4-dihydro-1*H*-pyrrolo[3,2,1*ij*]quinolin-1-ylidene)-2-thioxothiazolidin-4-one 9d









(Z)-5-(6-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-8-methoxy-4,4-dimethyl-2-oxo-2,4-dihydro-1*H*-pyrrolo[3,2,1-*ij*]quinolin-1-



ylidene)-2-thioxothiazolidin-4-one 9e







(Z)-5-(6-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-8-fluoro-4,4-dimethyl-2-oxo-2,4-dihydro-1*H*-pyrrolo[3,2,1*ij*]quinolin-1-ylidene)-2-thioxothiazolidin-4-one 9f







